title: [Treatment of spastic paraparesis with botulinum toxin with reference to beneficial effects, disease severity and long-term treatment].
abstract: We administered local botulinum toxin injections on the leg adductors of 12 patients with spastic paraparesis (9 patients with HAM, 2 patients with spinal spastic paraparesis, 1 patient with an identified degenerative disease). Two of them were wheelchair-bound and the other patients could walk with or without help. The patients were assessed by the time to walk 10 m and the spasticity score which was derived from the degree of muscle tone and spasm frequency of leg adductors. After the initial injection, 7 of the 12 patients improved spasticity scores and 8 of the 10 patients could walk 10 m within a shorter time. The time to walk 10 m was markedly shortened in moderate cases. However, one patient complained of leg weakness and the time to walk 10 m was prolonged. Five of the 12 patients received injections 3 to 7 times, and were followed up for a mean of 16.2 months. In 4 of the 5 patients, repeated injections could maintain the improvement of spasticity score and time to walk 10 m. However, injection was discontinued in one patient because of leg weakness. The other side effects were pain and swelling at the injected site and dysarthria. However, these side effects were slight and transient and did not require treatment. No other systemic side effects were observed. In conclusion, the beneficial effects of botulinum injections to spastic paraparesis were (1) improvement of objective symptoms in mild cases, (2) improvement of ADL in moderate cases, and (3) improvement of objective symptoms and ease of nursing care in severe cases. Furthermore, we confirmed the long-term efficacy and safety of botulinum toxin.
authors.affiliation: Third Department of Internal Medicine, Kagoshima University School of Medicine.
authors.forename: S
authors.initials: S
authors.lastname: Takenaga
authors.forename: Y
authors.initials: Y
authors.lastname: Kawahigashi
authors.forename: Y
authors.initials: Y
authors.lastname: Sonoda
authors.forename: T
authors.initials: T
authors.lastname: Horikiri
authors.forename: K
authors.initials: K
authors.lastname: Hirata
authors.forename: K
authors.initials: K
authors.lastname: Arimura
authors.forename: M
authors.initials: M
authors.lastname: Osame
mesh_terms: D000328:Adult; D000368:Aged; D001905:Botulinum Toxins / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D015493:Paraparesis, Tropical Spastic / Q000503:physiopathology / Q000628:therapy*; D016138:Walking
chemical_list: D001905:Botulinum Toxins